- Legislation Introduced to Codify Stem Cell Rules
- Commissioner Enhances FDA’s Commitment to Personalized Medicine
- Perfecting Policy on Stem Cells
- NIH and FDA Aim to Retool Regulatory Science
- DOE Leads Federal Funding for a Regional Innovation Cluster
- Certainty on the Science of Climate Change
- They’re Not Perfect Cells, But They’re Model Cells
- Genomic Medicine on the March
- President’s Budget Aims to Recharge Regional Innovation
- Event: The Science of Climate Change
- Progress in Bioethics
- The Top Science Progress Features of 2009
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
Gene Therapy: Vision Restored
A landmark for the most celebrated, and in some ways the most disappointing, late 20th century arena of medical research should not go without comment.
Last week, at the Children’s Hospital of Philadelphia, University of Pennsylvania researchers announced that they had used a genetically engineered virus to introduce a gene into the retinas of young adults with a form of congenital blindness that has no treatment, Leber congenital amaurosis (LCA). Within a few weeks all three patients had significant improvement in the treated eye, with no apparent side effects.
The only other successful gene transfer therapy trial took place in France, where children without functioning immune systems (”bubble-boy disease”) did achieve results, but several were diagnosed with leukemia thereafter. Following the success at CHOP, geneticists may now turn increasingly to single-gene disorders as the first therapeutic targets.
Katherine A. High, M.D, a Howard Hughes Medical Institute investigator and one of the CHOP study leaders, has been investigating LCA for years. For a field that has been racked by disappointment and controversy (the death of a gene therapy subject in 1998 at Penn shocked the scientific community), the good news from CHOP is both a source of encouragement and a reminder of the patience that is required to translate theoretical principles in genetics into practical treatments.
Comments on this article


